Search bioRxiv⌕ Search

Biology subjects

Gozzi, M.

Publications and source records attributed to Gozzi, M..

2 recordsLinked to original sources

Mutation-Induced Pocket Deactivation: How Ser353/Pro245 Alters KCa2.2 vs KCa3.1 Ligand Selectivity

The KCa2.2 and KCa3.1 channels are fundamental regulator of cellular K+ concentration, and promising target to treat diseases such as spinocerebellar ataxia and cancer. To fully exploit their therapeutic potential, and to continue studying their pathophysiological role, it is crucial to develop selective modulators for each of these two channels. Here we present a computational study to identify the molecular determinants behind the selectivity of two recently reported KCa2.2 modulators. We leveraged a protocol combining in silico mutagenesis, molecular dynamics simulations, and protein-ligand docking to analyse the pockets targeted by these ligands. We identified a Ser353/Pro245 substitution to be the main driver of the distinct pocket shapes in KCa2.2 and KCa3.1 channels, ultimately defining modulator selectivity. This approach provides novel insights into the structural differences of this binding site across potassium channel subtypes, shedding light on the selectivity determinants of modulators targeting this pocket.

pharmacology and toxicology↗

Discovery of the first small-molecule extracellular inhibitor of KCa3.1

The ion channel KCa3.1 plays a role in immune regulation, red blood cell function, and is linked to numerous types of cancer. Various animal toxins, such as maurotoxin, bind to the extracellular side of KCa3.1, providing a potential starting point for inhibitor development. We report in this work the discovery of a novel, small-molecule inhibitor, with a micromolar IC50, which was specifically designed to target plasma-membrane KCa3.1 channels from the extracellular side. This compound can serve as a starting point for the development of more selective inhibitors and probes. For the identification of new extracellular inhibitors, molecular dynamics simulations were performed using the experimental structures of KCa3.1 and maurotoxin. The simulations produced a validated binding mode, highlighting key residues involved in the interaction between the toxin and the channel. These findings laid the foundation for the structure-based identification of novel extracellular small-molecule inhibitors of KCa3.1. The Molport database, containing approximately 50 million compounds, was screened using protein-ligand docking, yielding a hit molecule that was experimentally confirmed using patch clamp assays.

pharmacology and toxicology↗